J.C. Miller et al. / The application of protein microarrays to serum diagnostics: Prostate cancer as a test case
233
[16] A.Q. Emili and G. Cagney, Large-scale functional analysis
using peptide or protein arrays, Nat. Biotech. 18 (2000), 393–
397.
[32] M.A. Hoffman, W.C. DeWolf and A. Morgentaler, Is low
serum free testosterone a marker for high grade prostate can-
cer? The Journal of Urology 163 (2000), 824–827.
[17] G. Walter, K. Buessow, D. Cahill, A. Lueking and H. Lehrach,
Protein arrays for gene expression and molecular interaction
screening, Curr. Opin. Microbio. 3 (2000), 298–302.
[18] B.B. Haab, Advances in protein microarray technology for
protein expression and interaction profiling, Curr. Opin. Drug
Disc. Dev. 4 (2001), 116–123.
[19] D. Cahill, Protein and antibody arrays and their medical ap-
plications, J. Immunol. Methods 250 (2001), 81–91.
[20] Prostate-specific antigen (PSA) best practice policy, Oncology
14 (1998), 267–286.
[21] M. Lukes, M. Urban, M. Zalesky, R. Zachoval, J. Heracek and
E. Zdarsky, Prostate-specific antigen: current status, Gynecol.
Oncol. 47 (2001), 41–49.
[22] P.B. Mehta, C.N. Robson, D.E. Neal and H.Y. Leung, Serum
keratinocyte growth factor measurement in patients with
prostate cancer, The Journal of Urology 164 (2000), 2151–
2155.
[23] M.K. Kwiatkowski, F. Recker, T. Piironen, K. Pettersson, T.
Otto, M. Wernli and R. Tscholl, In prostatism patients the ratio
of human glandular kallikrein to free PSA improves the dis-
crimination between prostate cancer and benign hyperplasia
within the diagnostic “gray zone” of total PSA 4 to 10 ng/mL,
Urology 52 (1998), 360–265.
[24] A. Magklara, A. Scorilas, W.J. Catalona and E.P. Diaman-
dis, The combination of human glandular kallikrein and free
prostate-specific antigen (PSA) enhances discrimination be-
tween prostate cancer and benign prostatic hyperplasia in pa-
tients with moderately increased total PSA, Clinical Chemistry
45 (1999), 1960–1966.
[33] A. Haese, C. Becker, J. Noldus, M. Graefen, E. Huland, H.
Huland and H. Lilja, Human glandular kallikrein 2: a po-
tential serum marker for predicting the organ confined versus
nonorgan confined growth of prostate cancer, The Journal of
Urology 163 (2000), 1491–1497.
[34] H. Dosaka-Akita, F. Hommura, T. Mishina, S. Ogura, M.
Shimizu, H. Katoh and Y. Kawakami, A Risk-Stratification
Model of Non-Small Cell Lung Cancers Using Cyclin E, Ki-
67, and ras p21, Cancer Research 61 (2001), 2500–2504.
[35] R.P. Woolas, M.R. Conaway, F. Xu, I.J. Jacobs, Y. Yu, L.
Daly, A.P. Davies, K. O’Briant, A. Berchuck, J.T. Soper, D.L.
Clarke-Pearson, G. Rodriguez, D.H. Oram and R.C.J. Bast,
Combinations of multiple serum markers are superior to indi-
vidual assays for discriminating malignant from benign pelvic
masses, Gynecologic Oncology 59 (1995), 111–116.
[36] W.J.P.A. Catalona, K.M. Slawin, M.K. Brawer, R.C. Flani-
gan, A. Patel, J.P. Richie, J.B. deKernion, P.C. Walsh, P.T.
Scardino, P.H. Lange, E.N. Subong, R.E. Parson, G.H. Gasior,
K.G. Loveland and P.C. Southwick, Use of the percentage
of free prostate-specific antigen to enhance differentiation of
prostate cancer from benign prostatic disease: a prospective
multicenter clinical trial, JAMA 279 (1998), 1542–1547.
[37] M.B. Eisen and P.O. Brown, DNA arrays for analysis of gene
expression, Methods Enzymol. 303 (1999), 179–205.
[38] B. Schweitzer, S. Wiltshire, J. Lambert, S. O’Malley, K.
Kukanskis, Z. Zhu, S.F. Kingsmore, P.M. Lizardi and D.C.
Ward, Imunoassays with rolling circle DNA amplification: a
versatile platform for ultrasensitive antigen detection, Proc.
Natl. Acad. Sci. USA 97 (2000), 10113–10119.
[25] W.-M. Zhang, P. Finne, J. Leinonen, J. Salo and U.-H. Sten-
man, Determination of prostate-specific antigen complexed
to alpha2-macroglobulin in serum increases the specificity of
free to total PSA for prostate cancer, Adult Urology 56 (2000),
267–272.
[39] I. Hedenfalk, D. Duggan, Y. Chen, M. Radmacher, M. Bittner,
R. Simon, P. Meltzer, B. Gusterson, M. Esteller, O.P. Kallion-
iemi, B. Wilfond, A. Borg and J. Trent, Gene-expression pro-
files in hereditary breast cancer, N. Engl. J. Med. 344 (2001),
539–548.
[26] R.W. Veltri, M.C. Miller, G. Zhao, A. Ng, G.M. Marley, G.L.J.
Wright, R.L. Vessella and D. Ralph, Interleukin-8 serum lev-
els in patients with benign prostatic hyperplasia and prostate
cancer, Urology 53 (1999), 139–147.
[27] C. Becker, T. Piironen, K. Pettersson, T. Bjork, K.J. Wo-
jno, J.E. Oesterling and H. Lilja, Discrimination of men with
prostate cancer from those with benign disease by measure-
ments of human glandular kallikrein 2 (hK2) in serum, The
Journal of Urology 163 (2000), 311–316.
[28] S. Akimoto, H. Inomiya, Y. Furuya, K. Akakura and H. Ito,
Prognostic value of the serum levels of bone formation and
bone resorption markers in prostate cancer patients with bone
metastasis, European Urology 34 (1998), 142–147.
[29] H. Miyake, I. Hara, K. Yamanaka, K. Gohji, S. Arakawa
and S. Kamidono, Elevation of serum levels of urokinase-
type plasminogen activator and its receptor is associated with
disease progression and prognosis in patients with prostate
cancer, The Prostate 39 (1999), 123–129.
[30] J. Nakashima, M. Tachibana, Y. Horiguchi, M. Oya, T. Ohi-
gashi, H. Asakura and M. Murai, Serum interleukin 6 as a
prognostic factor in patients with prostate cancer, Clinical
Cancer Research 6 (2000), 2702–2706.
[40] R. Hastie, R. Tibshirani, D. Botstein and P.O. Brown, Su-
pervised harvesting of expression trees, Genome Biology 2
(2001), research0003.1–research0003.12.
[41] M. Takahashi, D. Rhodes, K.A. Furge, H. Kanayama, S. Ka-
gawa, B.B. Haab and B.T. Teh, Gene expression profiling of
clear cell renal cell carcinoma: gene identification and prog-
nostic classification, Proc. Natl. Acad. Sci. USA 2001, in press.
[42] T.A. Stamey, N. Yang, A.R. Hay, J.E. McNeal, F.S. Freiha and
E. Redwine, Prostate-specific antigen as a serum marker for
adenocarcinoma of the prostate, N. Engl. J. Med. 317 (1987),
909–916.
[43] R. Baffa, K. Reiss, E.A. El-Gabry, J. Sedor, M.L. Moy, D.
Shupp-Byrne, S.E. Strup, W.W. Hauck, R. Baserga and L.G.
Gomella, Low serum insulin-like growth factor 1 (IGF-1):
a significant association with prostate cancer, Tech. Urol. 6
(2000), 236–239.
[44] M.H. Ahonen, L. Tenkanen, L. Teppo, M. Hakama and P.
Tuohimaa, Prostate cancer risk and prediagnostic serum 25-
hydroxyvitamin D levels, Cancer Causes Control 11 (2000),
847–852.
[45] R. Mazzucchelli, P. Colanzi, R. Pomante, G. Muzzonigro and
R. Montironi, Prostate tissue and serum markers, Adv. Clin.
Path. 4 (2000), 111–120.
[31] W. Lilleby, E. Paus, E. Skovlund and S.D. Fossa, Prognostic
value of neuroendocrine serum markers and PSA in irradiated
patients with pN0 localized prostate cancer, The Prostate 46
(2001), 126–133.
[46] H. Hilz, M. Graefen, J. Noldus, P. Hammeler, C. Knabbe, E.
Huland and H. Huland, Advanced prostate cancer is associated
with a decrease in serum luteinizing hormone, Eur. Urol. 38
(2000), 243–249.